The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

- Trade tensions escalate as Trump doubles down on tariff threats, targeting metals (steel, aluminum, copper), chips, and ...

The company’s plans may even continue to hinge on Keytruda, with Merck’s partnership alongside ... for ADCs has been something of a recurring theme for this type of treatment over its ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.

Analyst downgrades Salesforce to a sell rating due to slowing growth in key segments and AI posing a risk to revenue model.

Many health professionals are lining up against Trump's pick for health secretary. They say his anti-vaccine views could cost ...